Haleon PLC Sponsored ADR $HLN Stock Position Lowered by Fifth Third Bancorp

Fifth Third Bancorp reduced its position in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 25.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 227,648 shares of the company’s stock after selling 75,763 shares during the period. Fifth Third Bancorp’s holdings in Haleon were worth $2,042,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Brighton Jones LLC bought a new stake in shares of Haleon in the 4th quarter worth approximately $187,000. AQR Capital Management LLC lifted its position in shares of Haleon by 22.5% during the 1st quarter. AQR Capital Management LLC now owns 96,323 shares of the company’s stock valued at $991,000 after acquiring an additional 17,720 shares during the last quarter. Focus Partners Wealth boosted its stake in shares of Haleon by 7.6% during the 1st quarter. Focus Partners Wealth now owns 73,106 shares of the company’s stock worth $752,000 after acquiring an additional 5,178 shares in the last quarter. Geneos Wealth Management Inc. grew its holdings in shares of Haleon by 33.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after acquiring an additional 1,203 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of Haleon by 4.0% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 31,423 shares of the company’s stock worth $321,000 after acquiring an additional 1,200 shares during the last quarter. 6.67% of the stock is currently owned by institutional investors.

Haleon Stock Down 0.9%

HLN stock opened at $11.12 on Friday. The firm has a market cap of $49.50 billion, a PE ratio of 28.50 and a beta of 0.19. Haleon PLC Sponsored ADR has a 1 year low of $8.71 and a 1 year high of $11.42. The company has a fifty day simple moving average of $10.32 and a 200 day simple moving average of $9.75. The company has a current ratio of 0.87, a quick ratio of 0.63 and a debt-to-equity ratio of 0.48.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on HLN. Jefferies Financial Group reiterated a “buy” rating on shares of Haleon in a research report on Tuesday, January 20th. HSBC raised shares of Haleon from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 21st. Morgan Stanley reaffirmed an “overweight” rating on shares of Haleon in a research report on Monday, December 15th. Deutsche Bank Aktiengesellschaft lowered Haleon from a “hold” rating to a “sell” rating in a research report on Monday, January 12th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Haleon currently has an average rating of “Moderate Buy” and a consensus target price of $12.33.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.